Synonyms: ACT-001
Compound class:
Synthetic organic
Comment: ACT001 inhibits PD-L1 expression in neutrophils, and releases immune system suppression by the PD-1/PD-L1 checkpoint. It has potent anticancer and anti-inflammatory activities, and can cross the blood-brain barrier. The molecular mechanism of ACT001 is reported to involve direct interaction with the STAT3 transcription factor and inhibition of STAT3 phosphorylation [3,5]. In cancers that overexpress PD-L1 and escape immune surveillance, this offers a therapeutic strategy to enhance anti-tumour immune response. Some microbial pathogens upregulate PD-L1 expression in their hosts as a mechanism to negatively regulate the host anti-pathogen immune response [1-2,4,6-7]. By blocking PD-L1 expression ACT001 has been shown effective against systemic C. albicans infection [7]. However ACT001's high CNS permeability and strong cytotoxicity limit its use in the treatment of microbial infections. A sulphide ACT001 prodrug with an improved safety profile has been designed [3].
|
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
(3R,3aS,9R,9aS,9bS)-3-[(dimethylamino)methyl]-9-hydroxy-6,9-dimethyl-3,3a,4,5,7,8,9a,9b-octahydroazuleno[4,5-b]furan-2-one |
Synonyms |
ACT-001 |
Database Links | |
CAS Registry No. | 1403357-81-2 (source: PubChem) |
ChEMBL Ligand | CHEMBL2220079 |
GtoPdb PubChem SID | 496703261 |
PubChem CID | 52939461 |
Search Google for chemical match using the InChIKey | ZPBIJIIQXPRJSS-WNZSCWOMSA-N |
Search Google for chemicals with the same backbone | ZPBIJIIQXPRJSS |
UniChem Compound Search for chemical match using the InChIKey | ZPBIJIIQXPRJSS-WNZSCWOMSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | ZPBIJIIQXPRJSS-WNZSCWOMSA-N |